Vector Labs Ab03173-1.1 Anti-E protein [14D5], Mouse IgG1, kappa (200 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: 14D5
Synonyms: tick-borne encephalitis virus; TBEV; envelope domain III; EDIII; envelope protein
Amount: 200 μg
Application Codes Clone: ELISA; in vitro; in vivo; Neutralization; SPR; Crystallization
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG1
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement: This antibody binds a neutralizing epitope localized in domain III of glycoprotein E of TBEV between residues 301–339. Tick-borne encephalitis virus (TBEV) is a member of the tick-borne flaviviruses (TBFVs) in the family Flaviviridae which cause encephalomeningitis and encephalitis in humans and other animals.
Application Notes: The specificity of the IgG1 format was confirmed by ELISA analysis. The antibody was able to neutralize infectivity of TBEV in vitro (Tsekhanovskaya et al. 1993; PMID: 7505512). Two chimeric versions of the antibody were constructed, ch14D5a and ch14D5b, the affinity constants of which were 2.6 × 10^10 M−1 and 1.0 × 10^7 M−1, respectively, as determined by surface plasmon resonance. The chimeric ch14D5a and parental antibodies were analyzed for the neutralizing activity against TBEV strain 205 by FRNT. The neutralization index (IC50) of the chimeric version was 0.04 µg/ml and 0.5 µg/ml for the parental version. In vivo experiments using the chimeric ch14D5a version resulted in a 100% survival of the mice infected with 240 LD50 of TBEV at a dose of 10 µg/mouse. This chimeric antibody is promising for further development of prevention and therapeutic drugs against TBEV (Baykov et al., 2014; PMID: 24837772). The antibody was employed for in vivo experiments in BALB/c mice infected with TBEV, at doses of 100 µg and 10 µg of antibody per mouse. The antibody showed protective efficacy when injected at the high dose one day after infection, with survival rates that were TBEV dose-dependent, and complete protection when it was injected one day before infection. No protection was observed in mice received the low dose of the antibody (Matveev et al., 2020; PMID: 32409136). The crystal structure of the Fab fragment of the chimeric antibody in complex with the D3 domain of TBEV glycoprotein E was determined (Baykov et al., 2021). The antibody detected the EIII protein by western blot analysis (Stenkova et al., 2017; PMID: 28741465). Immunofluorescence was performed on Vero E6 cells using this antibody (Levanov et al. 2014, PMID: 24371235).

Product Class:	Purified
Clone ID:	14D5
Synonyms:	tick-borne encephalitis virus; TBEV; envelope domain III; EDIII; envelope protein
Amount:	200 μg
Application Codes Clone:	ELISA; in vitro; in vivo; Neutralization; SPR; Crystallization
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG1
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement:	This antibody binds a neutralizing epitope localized in domain III of glycoprotein E of TBEV between residues 301–339. Tick-borne encephalitis virus (TBEV) is a member of the tick-borne flaviviruses (TBFVs) in the family Flaviviridae which cause encephalomeningitis and encephalitis in humans and other animals.
Application Notes:	The specificity of the IgG1 format was confirmed by ELISA analysis. The antibody was able to neutralize infectivity of TBEV in vitro (Tsekhanovskaya et al. 1993; PMID: 7505512). Two chimeric versions of the antibody were constructed, ch14D5a and ch14D5b, the affinity constants of which were 2.6 × 10^10 M−1 and 1.0 × 10^7 M−1, respectively, as determined by surface plasmon resonance. The chimeric ch14D5a and parental antibodies were analyzed for the neutralizing activity against TBEV strain 205 by FRNT. The neutralization index (IC50) of the chimeric version was 0.04 µg/ml and 0.5 µg/ml for the parental version. In vivo experiments using the chimeric ch14D5a version resulted in a 100% survival of the mice infected with 240 LD50 of TBEV at a dose of 10 µg/mouse. This chimeric antibody is promising for further development of prevention and therapeutic drugs against TBEV (Baykov et al., 2014; PMID: 24837772). The antibody was employed for in vivo experiments in BALB/c mice infected with TBEV, at doses of 100 µg and 10 µg of antibody per mouse. The antibody showed protective efficacy when injected at the high dose one day after infection, with survival rates that were TBEV dose-dependent, and complete protection when it was injected one day before infection. No protection was observed in mice received the low dose of the antibody (Matveev et al., 2020; PMID: 32409136). The crystal structure of the Fab fragment of the chimeric antibody in complex with the D3 domain of TBEV glycoprotein E was determined (Baykov et al., 2021). The antibody detected the EIII protein by western blot analysis (Stenkova et al., 2017; PMID: 28741465). Immunofluorescence was performed on Vero E6 cells using this antibody (Levanov et al. 2014, PMID: 24371235).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews